Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations
NCT ID: NCT05664919
Last Updated: 2023-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
7000 participants
INTERVENTIONAL
2022-10-30
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SARS-CoV-2 Infection Among Healthcare Workers
NCT05680896
Evaluation of the Efficacy and Safety of Nano-S1
NCT05822180
Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)
NCT05244330
To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19
NCT04709328
The Safety and Efficacy of SCTA01 Against COVID-19 in Patients Admitted to High Dependence or Intensive Care
NCT04683328
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug group
3500 participants will use SA58 Nasal Spray in drug group.
SA58 Nasal Spray
SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
Blank control group
3500 participants won't be given medication in blank control group.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SA58 Nasal Spray
SA58 nasal spray , provided by Sinovac Life Sciences Co. , Ltd. mainly consists of neutralizing antibody of COVID-19, with 5 mg neutralizing antibody of COVID-19 per ml, 20 sprays per bottle.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects were 18 years of age and older and in good health;
* Subjects volunteered to use COVID-19 neutralizing antibody nasal spray.
Exclusion Criteria
* Women were pregnant or breastfeeding;
* Subjects were unable to cooperate with nasal spray inhalation;
* Other conditions for which medication was not appropriate.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sinovac Life Sciences Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shuo Zhang
Role: PRINCIPAL_INVESTIGATOR
Inner Mongolia Fourth Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Inner Mongolia Fourth Hospital
Hohhot, The Inner Mongolia Autonomous Region, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO-SA58-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.